Stifel Reiterates Bullish Stance on Esperion (ESPR) Following 'Clean' Data in Hypertensive Patients

Stifel analyst Thomas Shrader reiterated a Buy rating and $116 price target on Esperion Therapeutics (NASDAQ: ESPR) after the company released data from the 014 trial testing ETC-1002 in hypertensive patients – where the drug demonstrated neutrality on this important parameter.

Shrader commented, "This extreme attention to developing a safe drug is consistent with the company's goal of obtaining a label that is broader than the PCSK9 inhibitors. We reiterate our main point from Monday: Praluent was tested in patients with documented cardiovascular disease and got a label for these same patients. This group of 8-10 million patients is an attractive market for ETC-1002; but, we expect Esperion to conduct a Phase III program that includes a broader population consistent with a more inclusive label."

The analyst notes the company is hosting an analyst event Thursday.

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $71.65 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Infosys Technologies (INFY) PT Lowered to $18 at BMO Capital
• Knight Transportation (KNX) PT Lowered to $53 at Stifel